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Clostridium difficile infection (CDI) is the major cause 
of infective diarrhoea in healthcare environments. 
As part of the European, multicentre, prospective, 
biannual, point-prevalence study of Clostridium diffi-
cile infection in hospitalised patients with diarrhoea 
(EUCLID), the largest C. difficile epidemiological study 
of its type, PCR ribotype distribution of C. difficile 
isolates in Europe was investigated. PCR ribotyp-
ing was performed on 1,196 C. difficile isolates from 
diarrhoeal samples sent to the European coordinating 
laboratory in 2012–13 and 2013 (from two sampling 
days) by 482 participating hospitals from 19 European 
countries. A total of 125 ribotypes were identified, of 
which ribotypes 027 (19%, n =222), 001/072 (11%, n = 
134) and 014/020 (10%, n = 119) were the most preva-
lent. Distinct regional patterns of ribotype distribution 
were noted. Of 596 isolates from patients with toxin-
positive stools (CDI cases), ribotype 027 accounted 
for 22% (32/144) of infections in cases aged from 18 
to less than 65 years, but the prevalence decreased 
in those aged ≥ 65 years (14% (59/412)) and further 
decreased in those aged ≥ 81 years (9% (18/195)). The 
prevalence of ribotype 027 and 176, but not other epi-
demic strains, was inversely proportional to overall 
ribotype diversity (R2 = 0.717). This study highlights 
an increased diversity of C. difficile ribotypes across 
Europe compared with previous studies, with consid-
erable intercountry variation in ribotype distribution. 
Continuous surveillance programmes are necessary to 
monitor the changing epidemiology of C. difficile.
Introduction
Clostridium difficile is the most common cause of 
infective diarrhoea in hospitalised patients, and is 
associated with substantial morbidity and mortality. 
Over the past decade, the burden of C. difficile infec-
tion (CDI) has increased in many European countries, 
with the annual incidence in Europe estimated at 
124,000 cases in 2011–12 [1] with all-cause mortality 
rates of 3–30% [2-5]. CDI continues to be the focus of 
comprehensive national-level control and surveillance 
programmes in some countries, but the public health 
threat of CDI is not yet fully recognised across Europe.
C. difficile is an intensively typed pathogen, with a 
wide range of methods applied to understand its epi-
demiology. The emergence of so-called ‘hypervirulent’ 
C. difficile types has intensified the challenge of CDI. In 
the 1990s, strains belonging to PCR ribotype 027 (also 
referred to as restriction endonuclease type BI and 
North American pulsed-field type 1 (NAP-1)) were infre-
quently isolated from patients with CDI [6] but in the 
last decade this type has become highly represented 
among clinical isolates across Europe [7], with ribotype 
027 often linked to outbreaks with increased disease 
severity [8-10]. In a 2008 study of C. difficile epidemiol-
ogy in Europe, which consisted of a network of 106 lab-
oratories in 34 countries, 65 different ribotypes were 
identified, of which ribotypes 014/020 (16%), 001 (9%) 
and 078 (8%) were the most prevalent [11]. Ribotype 
027 accounted for 5% of all C. difficile isolates.
The European, multicentre, prospective, biannual, 
point-prevalence study of Clostridium difficile infection 
in hospitalised patients with diarrhoea (EUCLID) is the 
largest and most recent epidemiological study of C. dif-
ficile, encompassing 482 participating hospitals from 
20 European countries (Austria, Belgium, Bulgaria, 
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Czech Republic, Finland, France, Germany, Greece, 
Hungary, Ireland, Italy, the Netherlands, Poland, 
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden 
and United Kingdom (UK)) [12]. The study measured the 
prevalence and underdiagnosis of CDI on two sampling 
days (one in winter and one in summer) in 2012 and 
2013; participating hospitals forwarded inpatient diar-
rhoeal faecal samples to national coordinating labo-
ratories for CDI testing by a study reference method. 
The mean measured rate of CDI was 7.0 cases (coun-
try range 0.7–28.7) per 10,000 patient-bed days and, 
across all hospitals on the two sampling days, 148/641 
(23%) samples positive for CDI were not diagnosed by 
participating hospitals due to lack of clinical suspicion; 
a further 68 samples were not diagnosed due to sub-
optimal laboratory diagnostic methods [12]. 
Here, we report the PCR ribotype distribution of C. 
difficile isolates in Europe from the 1,211 samples, 
including those from 595 patients with confirmed CDI, 
that were culture positive for C. difficile in EUCLID and 
discuss the changing epidemiology of CDI from previ-
ous ribotype surveillance studies.
Methods
Study design
EUCLID followed the design of a previous point-preva-
lence study in Spain [13] and full methodology can be 
found in a previous EUCLID publication [12]. Briefly, the 
study was coordinated from the European coordinat-
ing laboratory in Leeds, UK. A national coordinating 
laboratory was selected for each of the 20 participat-
ing European countries and the national coordinators 
selected hospitals to cover all major geographical 
regions within each country. Hospitals were recruited 
at a rate of one per million population in all countries. 
All inpatient diarrhoeal samples submitted to the 
microbiology laboratory of the participating hospital 
on two sampling days (one day in winter, in December 
2012 or January 2013, and one day in summer, in July or 
August 2013) were eligible for inclusion. Anonymised 
samples were sent from the participating hospital, 
within seven days, to the national coordinating labora-
tory for their country, where they were tested for CDI 
and cultured for C. difficile. Transport was refrigerated 
for six countries (Finland, France, Hungary, Portugal, 
Romania and Spain) in the winter sampling period and 
for all 20 countries in the summer. 
Patients were defined as a CDI case if their faecal sam-
ple was positive according to a two-stage algorithm: 
membrane enzyme immunoassay for glutamate dehy-
drogenase and C. difficile toxins A and B (C DIFF QUIK 
CHEK COMPLETE, Techlab, United States). The inci-
dence of CDI in children aged under 2 years, in whom 
diarrhoeal illness is common and C. difficile carriage 
rates are high [14], is unclear [15,16]. Patients under 2 
years-old who tested positive for free toxin in the stool 
were therefore not included as cases of CDI. 
C. difficile colonisation of patients was assumed for 
those whose faecal sample was positive for culture of 
C. difficile but negative for free C. difficile toxin.
PCR ribotyping analysis
Isolates of C. difficile were stored in brain-heart infu-
sion broth supplemented with 10% glycerol at the 
national coordinating laboratories, before being frozen 
and transported to the European coordinating labo-
ratory in Leeds, UK. All C. difficile isolates identified 
at national coordinating laboratories (regardless of 
whether or not the samples were positive for glutamate 
dehydrogenase and free toxin, indicating CDI) were 
sent to Leeds, to confirm pathogen identification and 
for PCR ribotyping analysis. PCR ribotyping was per-
formed on all C. difficile isolates using the previously 
published capillary gel-based method [17].
Geographical distribution of ribotypes was based 
on the United Nations geoscheme for Europe [18]: 
Northern Europe (Finland, Ireland, Sweden and UK), 
Figure 1
Distribution of the 10 most commonly isolated 
Clostridium difficile PCR ribotypes from all C. difficile 
isolates in the participating countries, EUCLID, 2012–13 
and 2013a (n = 1,196)
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EUCLID: European, multicentre, prospective, biannual, point-
prevalence study of Clostridium difficile infection in hospitalised 
patients with diarrhoea.
The percentages are the based on the total number of ribotyped C. 
difficile isolates.
Data from the following countries (n= 19) were included: Austria, 
Belgium, Bulgaria, Czech Republic, Finland, France, Germany, 
Greece, Hungary, Ireland, Italy, the Netherlands, Poland, 
Portugal, Romania, Slovakia, Spain, Sweden and United 
Kingdom. None of the faecal samples submitted from Slovenia 
during the two sampling days were found to be positive for C. 
difficile or its toxins.
a The countries submitted inpatient diarrhoeal samples on two 
sampling days (one day in winter, in December 2012 or January 
2013, and one day in summer, in July or August 2013.
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Western Europe (Austria, Belgium, France, Germany 
and the Netherlands), Southern Europe (Greece, Italy, 
Portugal and Spain) and Eastern Europe (Bulgaria, 
Czech Republic, Hungary, Poland, Romania and 
Slovakia). None of the faecal samples submitted from 
Slovenia during the two sampling days were found to 
be positive for C. difficile or its toxins.
Statistical analyses
Simpson’s index (D) was used to compare diversity 
in ribotype distribution among countries and patient 
age groups, and was calculated as follows: D = Ʃ(n(n 
− 1))/N(N − 1), where n represents the total number of 
isolates of a particular ribotype and N represents the 
total combined number of isolates for all ribotypes. 
For ease of illustration, Simpson’s reciprocal index 
(1/D) was plotted, where the lowest possible diversity 
is 1 (a population dominated by a single ribotype) and 
increasing values indicate increasing diversity. 
Chi-squared test was used to compare the proportion 
of ribotypes from CDI cases among patient age groups.
Results
Samples obtained for PCR ribotyping analysis
A total of 3,923 and 3,389 faecal samples were sub-
mitted during the winter and summer testing periods, 
respectively. A total of 15 samples were excluded due 
to incomplete data, giving a total of 7,297 samples for 
analysis. 
A PCR ribotype was assigned to 1,194 of the 1,211 C. 
difficile isolates received by the European coordinating 
laboratory after removal of 17 sporadic isolates that 
could not be assigned to a ribotype (obtained from 19 
countries). For two samples more than one ribotype 
was isolated, giving a total of 1,196 C. difficile isolates. 
The median age of patients for whom a C. difficile 
PCR ribotype was reported was 71 years (range: 1–99) 
and patient ward locations included medical (n = 704), 
intensive therapy unit/high dependency unit (n = 47), 
obstetrics and gynaecology (n = 4), paediatric (n = 138) 
and surgery (n = 106).
Figure 2
Distribution of the 10 most commonly isolated Clostridium difficile PCR ribotypes in isolates from (A) cases of C. difficile 
infectiona (596 isolates) and (B) patients with likely colonisationb (600 isolates), EUCLID, 2012–13 and 2013c
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CDI: Clostridium difficile infection; EUCLID: European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile 
infection in hospitalised patients with diarrhoea.
The percentages shown are the based on the total number of ribotyped C. difficile isolates.
Data from the following countries (n = 19) were included: Austria, Belgium, Bulgaria, Czech Republic, Finland, France, Germany, Greece, 
Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden and United Kingdom. None of the faecal 
samples submitted from Slovenia during the two sampling days were found to be positive for C. difficile or its toxins.
a Positive for free C. difficile toxin, tested using a two-stage algorithm (membrane enzyme immunoassay for glutamate dehydrogenase and C. 
difficile toxins A and B).
b Positive for culture of C. difficile but negative for free C. difficile toxin.
c The countries submitted inpatient diarrhoeal samples on two sampling days (one day in winter, in December 2012 or January 2013, and one 
day in summer, in July or August 2013).
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C. difficile PCR ribotype diversity in Europe
We identified C. difficile isolates belonging to 125 dif-
ferent ribotypes across 19 countries; the 10 most com-
monly isolated ribotypes received by the European 
coordinating laboratory are shown in Figure 1. C. diffi-
cile ribotype 027 was the most prevalent (19%, n =222); 
ribotypes 001/072 (11%, n = 134) and 014/020 (10%, 
n = 119) were the second and third most prevalent, 
respectively. Ribotype 078, the third most prevalent 
ribotype in a previous study in 2008 [11], accounted for 
3% (n = 37) of isolates in our study.
Of the 1,196 C. difficile isolates where a PCR ribotype 
was identified, 596 were isolated from stool samples 
of 595 CDI cases (positive for free C. difficile toxin), 
while 600 were from 599 patients who were likely to be 
colonised (positive for culture of C. difficile but nega-
tive for free C. difficile toxin). The 10 most commonly 
Figure 3
PCR ribotype diversity of Clostridium difficile isolates by European regiona, EUCLID, 2012–13 and 2013b (n = 1,196)
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EUCLID: European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with 
diarrhoea.
The charts show the proportion of the most common ribotypes per region; the percentages are the based the number of typed isolates in the 
region.
a The 19 participating countries were classified by European region as defined according to the United Nations geoscheme for Europe [18]: 
(A) Northern Europe: Finland, Ireland, Sweden and United Kingdom; (B) Western Europe: Austria, Belgium, France, Germany and the 
Netherlands; (C) Southern Europe: Greece, Italy, Portugal and Spain; and (D) Eastern Europe: Bulgaria, Czech Republic, Hungary, Poland, 
Romania and Slovakia. None of the faecal samples submitted from Slovenia during the two sampling days were found to be positive for C. 
difficile or its toxins.
b The countries submitted inpatient diarrhoeal samples on two sampling days (one day in winter, in December 2012 or January 2013, and one 
day in summer, in July or August 2013).
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isolated ribotypes from samples from CDI cases (Figure 
2A) and those from patients with likely C. difficile colo-
nisation (Figure 2B) were compared. The ribotype dis-
tribution was found to be largely similar between CDI 
cases and patients with likely colonisation, suggesting 
no obvious over-representation of C. difficile isolates 
associated with colonisation or infection.
The geographical distribution of all C. difficile ribotypes 
isolated in this study is summarised in Figures 3 and 4. 
Many of the most commonly isolated ribotypes were 
Figure 4
Geographical distribution of Clostridium difficile PCR ribotypes, by participating European countrya, EUCLID, 2012–13 and 
2013b (n = 1,196)
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EUCLID: European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with 
diarrhoea.
Pie charts show the proportion of the most common ribotypes per country and the number in the centre of the charts is the number of typed 
isolates in the country.
a Austria, Belgium, Bulgaria, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, 
Romania, Slovakia, Spain, Sweden and United Kingdom. None of the faecal samples submitted from Slovenia during the two sampling days 
were found to be positive for C. difficile or its toxins.
b The countries submitted inpatient diarrhoeal samples on two sampling days (one day in winter, in December 2012 or January 2013, and one 
day in summer, in July or August 2013).
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found across each region (Figure 3). Among these were 
ribotype 001/072 (in 14 countries), 014/020 (in 16 
countries), 002 (in 12 countries), 078 (in 11 countries) 
and 027 (in 10 countries). However, we also observed 
substantial variation in ribotype distribution among 
the study countries (Figure 4). For example, ribotypes 
018 and 356 were commonly isolated in Italy (22% 
(28/129) and 17% (22/129) prevalence, respectively) 
but were rarely isolated in other countries. Similarly, 
ribotype 176, which is closely related to ribotype 027, 
represented 38% (13/34) of all isolates in the Czech 
Republic, but only 2% (26/1,196) of total isolates. 
Distinct regional patterns in the distribution of C. dif-
ficile ribotypes were noted (Figure 4).
The proportion of samples that were positive and 
negative for free C. difficle toxin received from each 
participating country was similar, suggesting that the 
geographical distribution of ribotypes was not influ-
enced by over- or under-representation of isolates 
associated with either CDI cases or likely colonisation.
Relationship between ribotype diversity and 
prevalence of ribotype 027
Given that most ribotype 027 strains were found to be 
localised mainly to four countries (Germany, Hungary, 
Poland and Romania) [12], we investigated the rela-
tionship between prevalence of ribotype 027 in the 
10 countries in which it was identified in EUCLID and 
the overall ribotype diversity among all C. difficile iso-
lates (from CDI cases and those with likely colonisa-
tion) received during the study from those countries. 
Using Simpson’s reciprocal index of diversity, we found 
that ribotype diversity decreased as the prevalence 
of ribotype 027 increased in the 10 countries where 
ribotype 027 was isolated (R2 = 0.717; Figure 5A). To 
determine whether this was a common feature of epi-
demic C. difficile types, we performed the same analy-
sis on ribotype 001/072 from the 14 countries where 
this type was isolated, but noted no obvious linear 
relationship between country ribotype diversity and 
prevalence of 001/072 (R2 = 0.032; Figure 5B). Taken 
together, these data suggest that countries with a high 
prevalence of ribotype 027 strains have a lower overall 
ribotype diversity than countries with a low prevalence 
of ribotype 027. 
A similar level of endemicity was observed in EUCLID 
for ribotype 176 in the Czech Republic (38% (13/34) of 
all ribotypes in the Czech Republic). C. difficile ribotype 
176 is thought to share many similarities to ribotype 
027 [19] and it has been suggested that this type may 
often be misdiagnosed as a ribotype 027 infection [20]. 
Therefore, we repeated this analysis to include both 
ribotype 027 and ribotype 176 and the findings were 
similar, with ribotype diversity decreasing as the prev-
alence of ribotypes 027 and 176 increased (R2  = 0.722; 
data not shown). This suggests that our observation 
is not limited to ribotype 027 and may extend to other 
closely related ribotypes with epidemic potential.
Figure 5
Relationship between Simpson’s reciprocal index of 
Clostridium difficile PCR ribotype diversity and EUCLID-
measured prevalencea of (A) ribotype 027b (n = 222) and 
(B) ribotype 001/072c (n = 134), EUCLID, 2012–13 and 
2013d
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EUCLID: European, multicentre, prospective, biannual, point-
prevalence study of Clostridium difficile infection in hospitalised 
patients with diarrhoea.
a As reported in [12].
b The 10 countries where ribotype 027 was isolated were Austria, 
Belgium, France, Germany, Hungary, Italy, Poland, Portugal, 
Romania, United Kingdom.
c The 14 countries where ribotype 001/072 was isolated were 
Bulgaria, Czech Republic, Finland, France, Germany, Hungary, 
Italy, Netherlands, Poland, Romania, Slovakia, Spain, Sweden, 
United Kingdom.
d The countries submitted inpatient diarrhoeal samples on two 
sampling days (one day in winter, in December 2012 or January 
2013, and one day in summer, in July or August 2013).
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Effect of patient age on C. difficile PCR 
ribotype distribution
A total of 596 C. difficile PCR ribotypes were iden-
tified from the faecal samples of 595 CDI-positive 
patients, aged 1–99 years, in the study. To investigate 
if ribotype diversity and distribution varied accord-
ing to patient age, we analysed the ribotype distribu-
tion in four patient age groups: 2 to < 18 years (n = 18), 
18 to < 65 years (n = 144), ≥ 65 years (n = 412) and ≥ 81 
years (n = 195). As the number of patients aged 2 to 
< 18 years was small, the combined age group of 2 to < 
65 years is shown (Figure 6). The ribotypes of isolates 
from samples of patients aged under 2 years were 
not included in the analysis, as the role of C. difficile 
in infants is uncertain. We found that the number of 
unique ribotypes identified increased with patient age. 
Figure 6
Clostridium difficile PCR ribotype diversity among patients with a confirmed diagnosis of C. difficile infection in the study, 
by age group (596 isolates from 595 CDI cases), EUCLID, 2012–13 and 2013a
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EUCLID: European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with 
diarrhoea.
The charts show the proportion of most common ribotypes per age group; the percentages are based on the number of typed isolates.
Data from the following countries (n = 19) were included: Austria, Belgium, Bulgaria, Czech Republic, Finland, France, Germany, Greece, 
Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden and United Kingdom. None of the faecal 
samples submitted from Slovenia during the two sampling days were found to be positive for C. difficile or its toxins.
a The countries submitted inpatient diarrhoeal samples on two sampling days (one day in winter, in December 2012 or January 2013, and one 
day in summer, in July or August 2013).
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When comparing two age groups with similar patient 
numbers, 39 individual ribotypes were isolated in 
patients aged 18 to < 65 years, while 59 were identified 
in patients ≥ 81 years. Analysis of Simpson’s reciprocal 
index of diversity showed that overall ribotype diver-
sity was higher in patients aged ≥ 81 years (Simpson’s 
reciprocal index: 21.16) than in those aged 18 to < 65 
years (Simpson’s reciprocal index: 10.1). 
Ribotype 001/072 was commonly found in all age 
groups, with no obvious differences in distribution 
according to patient age (13% (n = 19/144) in CDI cases 
aged 18 to < 65 years, 10% (n = 42/412) in ≥ 65 year-olds 
and 14% (n = 27/195) in ≥ 81 year-olds). Other commonly 
isolated ribotypes, such as 014/020 (11% (n = 16/144), 
8% (n = 32/412) and 9% (n = 18/195), respectively) 
and 078 (3% (n = 5/144), 3% (n = 13/412) and 3% (n = 
6/195), respectively) were also consistently found in all 
patient age groups, with no noticeable age-associated 
variation in prevalence (patients aged 2 to < 18 years 
were excluded from this analysis due to the small sam-
ple size). 
Ribotype 027 occurred in all patient age groups but 
we observed considerable variation in prevalence. 
While this ribotype accounted for 22% (n = 32/144) 
of CDI cases aged 18 to < 65 years, the prevalence was 
significantly lower in those aged ≥ 65 years (14%, n = 
59/412) and was significantly further decreased in 
those aged ≥ 81 years (9%, n = 18/195) (chi-squared 
test p = 0.001). 
To exclude any bias from country-specific variation 
in our analysis, we investigated the differences in 
ribotype distribution in CDI cases aged 18 to < 65 years 
(n = 51) and ≥ 65 years (n = 172) from participating hos-
pitals in Germany (the largest country in the study). 
We observed a similar trend, with the prevalence of 
ribotype 027 in patients aged 18 to < 65 years (33%, n = 
17/51) double that of the prevalence in those aged ≥ 65 
years (15%, n = 26/172).
We observed that of 117 isolated C. difficile ribotypes 
from patients aged under 2 years, only 22 (18.8%) were 
associated with a positive test result for detection of 
free C. difficile toxin in the stool sample. By contrast, 
26.5% (18/68) of ribotypes isolated from patients aged 
2 to < 18 years, 48.6% (144/296) from those aged 18 to 
< 65 years, 57.6% (412/712) from those aged ≥ 65 years 
and 60.6% (195/322) from those aged ≥ 81 years were 
associated with positive test results; the differences in 
the rates of toxin-positive test results among these age 
groups were statistically significant (p < 0.001). This 
finding supports the view that detection of C. difficile 
in infants and neonates often reflects asymptomatic 
colonisation. 
Interestingly, ribotype 356 was commonly isolated in 
those aged under 2 years (4/22) but was rarely seen in 
those ≥ 65 years (2%, 7/412) and was not found at all 
in patients aged 2 to < 65 or ≥ 81 years. This suggests 
that ribotype 356 may be more commonly found in 
infants and neonates than older patients, although 
more data from a larger sample are required to verify 
this observation.
Discussion
The findings of this EUCLID analysis highlight the 
changing epidemiology of C. difficile in Europe. We 
found an increase in overall ribotype diversity, with 
more than double the number of ribotypes identified 
in this study compared with data from 2008 [11]. It is 
important to note, however, that the possible subop-
timal testing methodology and selection of cases for 
isolate ribotyping in the previous study, in addition to 
the smaller sample size, would likely have led to an 
under-representation of the recorded strain diversity. 
Nevertheless, notably, the prevalence of ribotype 027 
had increased more than threefold (from 5% to 18.6%) 
since 2008 [11] and 027 was the most commonly iso-
lated ribotype in the participating European countries 
in our study (on two sampling days in 2012–13 and 
2013). 
No clear difference in ribotype distribution was 
observed when samples that tested positive for free 
C. difficile toxin were compared with those that tested 
negative . This suggests that there is no discernible 
difference in those ribotypes causing C. difficile dis-
ease and those involved with colonisation, at least in 
inpatients with diarrhoea. The toxin component of the 
testing algorithm used in our study has been reported 
to have a sensitivity of 67.3% in the combined test and 
84.3% as a single assay [21,22]. Thus, some patients 
classified here as likely colonised will in fact have been 
missed CDI cases.
Some similarities with the 2008 study [11] were 
observed, with ribotype 001/072 and ribotype 014 
remaining highly prevalent among C. difficile clinical 
isolates across many European countries. However, we 
observed an almost threefold reduction in the preva-
lence of ribotype 078 in this study compared with that 
in 2008 [11]. Also, ribotype 106, which was associated 
with 26% and 20% of CDI cases in England in 2005 [23] 
and 2007–08 [24], respectively, was not found at all in 
the UK study hospitals in our study and accounted for 
only 0.6% of all C. difficile isolates in Europe. Ribotype 
027 previously accounted for 55% of isolates in England 
in 2007–08 [25], but only represented 2.3% of UK iso-
lates in the present study. 
Our previous analysis showed a clear shift in ribotype 
027 endemicity, from the UK and Ireland in 2008 to 
Germany, Hungary, Poland and Romania on the two 
sampling days in 2012–13 and 2013 [12]. The reason 
for a shift in ribotype 027 prevalence towards Germany 
and Eastern Europe is not clear, but may have been 
influenced by national CDI testing policies. Our ear-
lier analysis identified an inverse correlation between 
the rate of CDI testing and prevalence of ribotype 027 
across Europe [12]. Thus, an increased awareness of 
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CDI, via the use of optimum diagnostic tests, may have 
permitted the implementation of more timely infection 
prevention and antimicrobial prescribing interventions 
in Northern Europe, and so better control of epidemic 
strains such as ribotype 027 in this region since 2008 
[12].
The substantial variation in ribotype distribution 
observed among study countries and regions is in 
keeping with the results of the 2008 study, in which 
the most commonly isolated C. difficile ribotypes were 
found in many countries across Europe and the geo-
graphical distribution of some ribotypes suggested 
regional spread [11]. Our findings highlight the diverse 
epidemiology of C. difficile across Europe. We observed 
that a high prevalence of ribotypes 027 and 176 was 
associated with low overall country-specific ribotype 
diversity, which is perhaps unsurprising. Countries 
with CDI outbreaks caused by epidemic strains such as 
ribotypes 027 and 176 would likely have high incidence 
rates but lower overall diversity due to more health-
care-associated transmission of dominant ribotypes. 
This scenario may have been seen first-hand in the UK, 
where CDI incidence rapidly increased in 2006 with the 
emergence of ribotype 027 [23-25]. Subsequent infec-
tion control measures and antibiotic stewardship may 
have since shifted the UK into an endemic scenario 
with high ribotype diversity and a low prevalence of 
ribotype 027 [26]. 
We found no correlation between ribotype 001/072 
prevalence and overall ribotype diversity, suggesting 
that ribotypes 027 and 176 may be more successful 
at outcompeting such other ribotypes with epidemic 
potential. The drivers for dominant ribotypes in par-
ticular countries, for example ribotype 176 in the 
Czech Republic and ribotype 018 in Italy, are not yet 
known. In the UK, the practice of restricting precrip-
tions of cephalosporins and fluoroquinolones since 
2009 has been associated with falling prevalence of 
ribotype 027, which suggests that reduced selection of 
antibiotic-resistant (in this case, fluoroquinolones) C. 
difficile clones could be a key control measure [25,27]. 
Future studies of comparative fitness among different 
C. difficile ribotypes would be of particular interest.
The observed differences in ribotype distribution for 
CDI cases among patient age groups also suggest 
that some ribotypes may be more likely to cause CDI. 
Of note was the significant reduction in ribotype 027 
prevalence with increasing patient age, which is per-
haps at odds with the known poor clinical outcomes 
associated with this strain type in elderly patients 
[28]. It is possible that our data reflect differences in 
C. difficile selection pressures according to age; for 
example, less frequent use of high CDI-risk antibiotics 
in elderly patients [29,30]. Overall ribotype diversity 
appeared to increase with age, which may be related 
to the observed inverse correlation between ribotype 
diversity and 027 prevalence. 
We noted the presence of some known non-toxigenic C. 
difficile types among isolates associated with CDI posi-
tive tests, with ribotypes 140 (3.7%) and 010 (3.5%) 
the fourth and sixth most commonly isolated in the 
participating countries in Europe, respectively. A likely 
explanation for this finding is that the submitted fae-
cal sample contained more than one ribotype (includ-
ing toxigenic ribotypes responsible for a positive toxin 
test) but, when C. difficile was cultured, the predomi-
nant strain was ribotype 140 or 010. The rate of mixed 
C. difficile genotypes in faecal samples of patients with 
CDI has ranged from 7% to 13% in previous studies [31-
34] and the coexistence of multiple PCR ribotypes has 
been previously reported as a potential limitation of 
C. difficile epidemiological studies [35]. In our study, 
several single C. difficile colonies were pooled before 
DNA extraction and, while this method allows accurate 
identification of the predominant ribotype, not every 
ribotype present within the sample can be identified. 
Therefore, in some cases the relative abundance of the 
disease-causing ribotype may have been too low for 
identification.
The findings of this analysis from EUCLID emphasise 
the importance of continuous national and European 
surveillance programmes to monitor the dynamic epi-
demiology of C. difficile, including use of optimal diag-
nostic methods to identify CDI cases. Further studies 
are also necessary to better understand how C. diffi-
cile ribotype distribution varies among patient popula-
tions, and factors contributing to an observed shift of 
ribotype 027 to Germany and Eastern Europe.
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